India, Oct. 19 -- Belite Bio, Inc. (BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, announced that Nasdaq approved the transfer of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026.
The company will continue trading under its existing ticker symbol, BLTE. The Nasdaq Global Select Market is the exchange's highest market tier and has more stringent financial and liquidity requirements.
Belite Bio said the uplisting reflects its progress in strengthening its financial profile and capital markets presence. The company expects the move to enhance visibility among institutional investors, improve liquidity and broaden market recognition.
Belit...